Literature DB >> 23241649

Effects of the 5HT2C antagonist SB242084 on the pramipexole-induced potentiation of water contrafreeloading, a putative animal model of compulsive behavior.

Chiara Schepisi1, Lorenza De Carolis, Paolo Nencini.   

Abstract

RATIONALE: In rats, quinpirole, a dopaminergic D2/D3 receptor agonist, elicits both hyperdipsia and water "contrafreeloading" (CFL), a putative model of compulsivity. The role of D3 receptors in this effect remains unclear. Clomipramine (CIM) was found to contrast both hyperdipsia and CFL, but the role of serotonin in this effect requires further investigation.
OBJECTIVES: We studied the effects of the preferential D3 agonist pramipexole (PPX) in both models. Furthermore, we tested the sensitivity of PPX-induced CFL to CIM and to the 5HT2c antagonist SB242084.
METHODS: In experiment 1, drinking was measured at 2 and 5 h after eight daily injections of PPX (0 to 1.0 mg/kg intraperitoneally). In the CFL study, every other third lever press, the rat was reinforced by the delivery of water. On days 1-6, water was only available upon lever pressing. On days 7-15, choice between response-contingent and free access was provided. PPX doses as in the experiment 1 were given. In two further experiments, PPX (0.5 mg/kg) was administered alone or in combination with CIM (5 or 10 mg/kg) or SB242084 (0.3 or 1.0 mg/kg).
RESULTS: PPX did not produce hyperdipsia but enhanced spontaneous CFL. SB242084 attenuated PPX-induced CFL more effectively than CIM, restoring the preference for free access to water.
CONCLUSIONS: CFL, but not polydipsia, was induced by preferential D3 activation, an effect prevented by 5HT2c receptor blockade. Since PPX interferes with decision making and 5HT2c receptor supersensitivity is involved in the expression of compulsive behaviors, this study supports the compulsive nature of dopaminergic-induced CFL.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23241649     DOI: 10.1007/s00213-012-2938-z

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  70 in total

1.  Pathophysiological modeling of obsessive-compulsive disorder: challenges, and progress.

Authors:  Christopher Pittenger
Journal:  Biol Psychiatry       Date:  2011-12-01       Impact factor: 13.382

Review 2.  The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease.

Authors:  Susan H Fox; Regina Katzenschlager; Shen-Yang Lim; Bernard Ravina; Klaus Seppi; Miguel Coelho; Werner Poewe; Olivier Rascol; Christopher G Goetz; Cristina Sampaio
Journal:  Mov Disord       Date:  2011-10       Impact factor: 10.338

3.  Pramipexole modulates the neural network of reward anticipation.

Authors:  Zheng Ye; Anke Hammer; Estela Camara; Thomas F Münte
Journal:  Hum Brain Mapp       Date:  2011-05       Impact factor: 5.038

4.  Clomipramine, but not haloperidol or aripiprazole, inhibits quinpirole-induced water contrafreeloading, a putative animal model of compulsive behavior.

Authors:  Lorenza De Carolis; Chiara Schepisi; Michele S Milella; Paolo Nencini
Journal:  Psychopharmacology (Berl)       Date:  2011-06-10       Impact factor: 4.530

5.  Association between stereotypic behavior and polydipsia in chronic schizophrenic patients.

Authors:  M S Shutty; K McCulley; B Pigott
Journal:  J Behav Ther Exp Psychiatry       Date:  1995-12

6.  Opposite roles of dopamine and orexin in quinpirole-induced excessive drinking: a rat model of psychotic polydipsia.

Authors:  Michele S Milella; Francesca Passarelli; Lorenza De Carolis; Chiara Schepisi; Paola Nativio; Sergio Scaccianoce; Paolo Nencini
Journal:  Psychopharmacology (Berl)       Date:  2010-06-16       Impact factor: 4.530

7.  Quinpirole- and amphetamine-induced hyperdipsia: influence of fluid palatability and behavioral cost.

Authors:  I Cioli; A Caricati; P Nencini
Journal:  Behav Brain Res       Date:  2000-04       Impact factor: 3.332

8.  The cortical serotonin2 receptors studied with positron-emission tomography and [18F]-setoperone during depressive illness and antidepressant treatment with clomipramine.

Authors:  D Attar-Lévy; J L Martinot; J Blin; M H Dao-Castellana; C Crouzel; B Mazoyer; M F Poirier; M C Bourdel; N Aymard; A Syrota; A Féline
Journal:  Biol Psychiatry       Date:  1999-01-15       Impact factor: 13.382

9.  The influence of cost manipulation on water contrafreeloading induced by repeated exposure to quinpirole in the rat.

Authors:  Michele S Milella; Davide Amato; Aldo Badiani; Paolo Nencini
Journal:  Psychopharmacology (Berl)       Date:  2008-01-12       Impact factor: 4.530

10.  Serotonin and dopamine play complementary roles in gambling to recover losses.

Authors:  Daniel Campbell-Meiklejohn; Judi Wakeley; Vanessa Herbert; Jennifer Cook; Paolo Scollo; Manaan Kar Ray; Sudhakar Selvaraj; Richard E Passingham; Phillip Cowen; Robert D Rogers
Journal:  Neuropsychopharmacology       Date:  2010-10-27       Impact factor: 7.853

View more
  9 in total

1.  Separate mechanisms for development and performance of compulsive checking in the quinpirole sensitization rat model of obsessive-compulsive disorder (OCD).

Authors:  Mark C Tucci; Anna Dvorkin-Gheva; Renee Sharma; Leena Taji; Paul Cheon; John Peel; Ashley Kirk; Henry Szechtman
Journal:  Psychopharmacology (Berl)       Date:  2014-02-28       Impact factor: 4.530

2.  Activation of serotonin 5-HT2A receptors inhibits high compulsive drinking on schedule-induced polydipsia.

Authors:  Silvia Victoria Navarro; Valeria Gutiérrez-Ferre; Pilar Flores; Margarita Moreno
Journal:  Psychopharmacology (Berl)       Date:  2014-08-26       Impact factor: 4.530

Review 3.  Obsessive-compulsive disorder: Insights from animal models.

Authors:  Henry Szechtman; Susanne E Ahmari; Richard J Beninger; David Eilam; Brian H Harvey; Henriette Edemann-Callesen; Christine Winter
Journal:  Neurosci Biobehav Rev       Date:  2016-05-07       Impact factor: 8.989

4.  Evidence for a role of 5-HT2C receptors in the motor aspects of performance, but not the efficacy of food reinforcers, in a progressive ratio schedule.

Authors:  G Bezzina; S Body; T H C Cheung; C L Hampson; C M Bradshaw; J C Glennon; E Szabadi
Journal:  Psychopharmacology (Berl)       Date:  2014-08-19       Impact factor: 4.530

5.  Increased motor impulsivity in a rat gambling task during chronic ropinirole treatment: potentiation by win-paired audiovisual cues.

Authors:  Melanie Tremblay; Michael M Barrus; Paul J Cocker; Christelle Baunez; Catharine A Winstanley
Journal:  Psychopharmacology (Berl)       Date:  2019-01-31       Impact factor: 4.530

6.  Inhibition of hippocampal plasticity in rats performing contrafreeloading for water under repeated administrations of pramipexole.

Authors:  Chiara Schepisi; Annabella Pignataro; Salvatore Simone Doronzio; Sonia Piccinin; Caterina Ferraina; Silvia Di Prisco; Marco Feligioni; Anna Pittaluga; Nicola Biagio Mercuri; Martine Ammassari-Teule; Robert Nisticò; Paolo Nencini
Journal:  Psychopharmacology (Berl)       Date:  2015-11-17       Impact factor: 4.530

7.  Differences in the structure of drinking, cart expression and dopamine turnover between polydipsic and non polydipsic rats in the quinpirole model of psychotic polydipsia.

Authors:  Chiara Schepisi; Silvia Cianci; Gaurav Bedse; Jin Fu; Silvana Gaetani; Paolo Nencini
Journal:  Psychopharmacology (Berl)       Date:  2014-03-20       Impact factor: 4.530

Review 8.  Validity of Quinpirole Sensitization Rat Model of OCD: Linking Evidence from Animal and Clinical Studies.

Authors:  Ales Stuchlik; Dominika Radostová; Hana Hatalova; Karel Vales; Tereza Nekovarova; Jana Koprivova; Jan Svoboda; Jiri Horacek
Journal:  Front Behav Neurosci       Date:  2016-10-26       Impact factor: 3.558

9.  Behavioral Biomarkers of Schizophrenia in High Drinker Rats: A Potential Endophenotype of Compulsive Neuropsychiatric Disorders.

Authors:  Silvia V Navarro; Roberto Alvarez; M Teresa Colomina; Fernando Sanchez-Santed; Pilar Flores; Margarita Moreno
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.